News Posted on
New York, 09 September: British-Swedish bio-pharma company ‘Astra Zeneca’ on Tuesday halted the clinical trial of the third and final phase of the vaccine being developed for a corona infection.
A company spokesperson said that during the clinical trial, there was a serious and suspected adverse reaction in one participant from injection of the vaccine.
However, it is not yet known whether this ‘reaction’ is directly due to the company’s vaccine or coincidentally.
The AstraZeneca Company has been involved in the vaccine’s safety review and investigation process.
The spokesperson claimed that clinical trials being conducted on such a large scale often lead to one or two incidents.
Clinical trials are being conducted on 17,000 participants in Britain, USA and Brazil regarding this vaccine, said company spokesman.
More than 8, 90,000 people have died worldwide due to Covid-19 and millions of people around the world are eyeing a perfect vaccine.
However, AstraZeneca is a front-runner. It is expected to have a vaccine ready before the end of the year. If there is a reaction with the injection of this vaccine, then it can be a serious issue.
The New York Times at the University of California, San Francisco, said infectious disease specialist Dr Felice Tien, “We need to assess safety. Until now the Safety Board finds out whether the said response was directly related to the vaccine. It is a good idea to stop the clinical trial.”
President Donald Trump has been making claims to bring the Corona vaccine to market before the presidential election date of November 3.
In this context, on Tuesday, nine companies, including ‘AstraZeneca’, have pledged to “stand with the science” on vaccines of coronovirus.
They have assured that every step about its safety and effectiveness till its delay will be confirmed on scientific basis before launching the vaccine in the market. This fact has also been considered by the AstraZeneca Company.
The spokesperson has said that sometimes one to two participants get sick accidentally during a large-scale trial, but it is important to review it independently to be carefully watched.